Rory Michael Shallis (Rory Shallis, Amer M Zeidan, Rory M Shallis)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 49

Top Topics

African American

Stem Cell Transplantation

Top Venues

Leukemia & lymphoma

Expert review of hematology

This page only lists publications with an associated author ORCID identifier.

Publications

Nikolai A Podoltsev, Rong Wang, Rory Michael Shallis, Jessica M Stempel, Mengyang Di, Natalia Neparidze, Amer M Zeidan, Scott F Huntington, Smith Giri, Sarah C Hull, Steven D Gore, Xiaomei Ma
Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer medicine (2023)
Talha Badar, Ehab Atallah, Rory Michael Shallis, Antoine N Saliba, Anand Ashwin Patel, Jan P Bewersdorf, Justin Grenet, Maximilian Stahl, Adam Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Michal Kubiak, Shira Dinner, Aaron D Goldberg, Yasmin Abaza, Guru Subramanian Guru Murthy, Vamsi K Kota, Mark R Litzow
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia (2023)
Sangeetha Venugopal, Rory Michael Shallis, Amer M Zeidan
Oral therapy for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a revolution in progress. Expert review of anticancer therapy (2023)
Rory Michael Shallis, Rong Wang, Amer M Zeidan, Scott F Huntington, Natalia Neparidze, Jessica M Stempel, Lourdes M Mendez, Mengyang Di, Xiaomei Ma, Nikolai A Podoltsev
Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood advances (2023)
Rong Wang, Rory Michael Shallis, Jessica M Stempel, Scott F Huntington, Amer M Zeidan, Steven D Gore, Xiaomei Ma, Nikolai A Podoltsev
Second Malignancies among Older Patients with Classical Myeloproliferative Neoplasms Treated with Hydroxyurea. Blood advances (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Natalia Neparidze, Rong Wang, Amer M Zeidan, Nikolai A Podoltsev, Rory Michael Shallis, Xiaomei Ma, Amy J Davidoff, Scott F Huntington
Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period. Leukemia 36 (8) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Rory Michael Shallis, Naval G Daver, Jessica K Altman, Robert P Hasserjian, Hagop M Kantarjian, Uwe Platzbecker, Valeria Santini, Andrew H Wei, David A Sallman, Amer M Zeidan
TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity. Cancer (2022)
Mengyang Di, Can Cui, Shalin K Kothari, Amer M Zeidan, Nikolai A Podoltsev, Natalia Neparidze, Rory Michael Shallis, Rong Wang, Xiaomei Ma, Scott F Huntington
Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis. Blood advances 6 (11) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Amer M Zeidan, Jan Philipp Bewersdorf, Vanessa Hasle, Rory Michael Shallis, Ethan Thompson, Daniel Lopes de Menezes, Shelonidta Rose, Isaac Boss, Stephanie Halene, Torsten Haferlach, Brian Fox
Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy. Leukemia (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Maximilian Stahl, Eytan M Stein, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1 -mutant acute myeloid leukemia. Leukemia & lymphoma 64 (2) (2022)
Jan Philipp Bewersdorf, Kishan K Patel, George Goshua, Rory Michael Shallis, Nikolai A Podoltsev, Scott F Huntington, Amer M Zeidan
Cost-effectiveness of liposomal cytarabine/daunorubicin in patients with newly diagnosed acute myeloid leukemia. Blood 139 (11) (2022)
Jan Philipp Bewersdorf, Rory Michael Shallis, Andriy Derkach, Aaron D Goldberg, Anthony Stein, Eytan M Stein, Guido Marcucci, Amer M Zeidan, Shai Shimony, Daniel J DeAngelo, Richard M Stone, Ibrahim Aldoss, Brian J Ball, Maximilian Stahl
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & lymphoma (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer (2022)
Rory Michael Shallis, Jan P Bewersdorf, Maximilian F Stahl, Stephanie Halene, Amer M Zeidan
Are We Moving the Needle for Patients with TP53 -Mutated Acute Myeloid Leukemia? Cancers 14 (10) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Talha Badar, Mark R Litzow, Rory Michael Shallis, Anand Ashwin Patel, Antoine N Saliba, Madelyn Burkart, Jan Philipp Bewersdorf, Maximilian Stahl, Guilherme Sacchi De Camargo Correia, Guru Subramanian Guru Murthy, Yasmin M Abaza, Adam Duvall, Danielle Bradshaw, Vamsi K Kota, Shira Dinner, Aaron D Goldberg, Neil Palmisiano, Aref Al Kali, Ehab Atallah
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer 129 (6) (2022)
Rory Michael Shallis, Steven D Gore
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis. Leukemia & lymphoma 63 (7) (2022)
Jan Philipp Bewersdorf, Stephanie Prozora, Nikolai A Podoltsev, Rory Michael Shallis, Scott F Huntington, Natalia Neparidze, Rong Wang, Amer M Zeidan, Amy J Davidoff
Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States. Blood advances (2021)
Rory M Shallis, Rory Michael Shallis
Management of the Older Patient with Myelodysplastic Syndrome. Drugs & aging 38 (9) (2021)
Rory Michael Shallis, Darko Pucar, Sudhir Perincheri, Steven D Gore, Stuart E Seropian, Nikolai A Podoltsev, Amer M Zeidan
Molecular testing of isolated myeloid sarcoma allows successful FLT3-targeted therapy. Annals of hematology (2021)
Rory Michael Shallis, Rong Wang, Jan Philipp Bewersdorf, Amer M Zeidan, Amy J Davidoff, Scott F Huntington, Nikolai A Podoltsev, Xiaomei Ma
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States. Therapeutic advances in hematology 12 (2021)
Rory Michael Shallis, Maximilian Stahl, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukhereje, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël Itzykson, Blanca Boluda, Florence Rabian, María Del Mar Tormo Díaz, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & lymphoma 61 (5) (2020)
Rory Michael Shallis, Maximilian Stahl, Jan Philipp Bewersdorf, Jeanne E Hendrickson, Amer M Zeidan
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert review of hematology 13 (5) (2020)
Jan Philipp Bewersdorf, Rory Michael Shallis, Autumn Diadamo, Lohith Gowda, Nikolai A Podoltsev, Alexa Siddon, Amer M Zeidan
Isolated trisomy 11 in patients with acute myeloid leukemia - is the prognosis not as grim as previously thought? Leukemia & lymphoma 61 (9) (2020)
Jennifer Zhao, Jan Philipp Bewersdorf, Sara Jaszczur, Andrew Kowalski, Sarah Perreault, Molly Schiffer, Steven Gore, Nikolai Podoltsev, Thomas Prebet, Rory Michael Shallis, Amer M Zeidan
High dose cyclophosphamide for cytoreduction in patients with acute myeloid leukemia with hyperleukocytosis or leukostasis. Leukemia & lymphoma 62 (5) (2020)
Maximilian Stahl, Rory Michael Shallis, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina M Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukherjee, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël A Itzykson, Blanca Boluda, Florence Rabian, Mar Tormo, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 34 (12) (2020)
Jan Philipp Bewersdorf, Rory Michael Shallis, Lohith Gowda, Wei Wei, Karl Hager, Iris Isufi, Tae Kon Kim, Manoj M Pillai, Stuart Seropian, Nikolai A Podoltsev, Steven D Gore, Alexa J Siddon, Amer M Zeidan
Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leukemia & lymphoma 61 (9) (2020)
Rory Michael Shallis, Nikolai A Podoltsev, Lohith Gowda, Amer M Zeidan, Steven D Gore
Cui bono? Finding the value of allogeneic stem cell transplantation for lower-risk myelodysplastic syndromes. Expert review of hematology 13 (5) (2020)
Rory Michael Shallis, Shana Gleeson, Marwan M Azar, Maricar Malinis, Mina L Xu, Stuart E Seropian, Lohith Gowda, Amer M Zeidan
Allogeneic stem cell transplantation and combination antiretroviral therapy: cautions, complications, and considerations. Leukemia & lymphoma 60 (10) (2019)
Jan Philipp Bewersdorf, Rory Michael Shallis, Rong Wang, Scott F Huntington, Sarah Perreault, Xiaomei Ma, Amer M Zeidan
Healthcare expenses for treatment of acute myeloid leukemia. Expert review of hematology 12 (8) (2019)
Nora Chokr, Alexander B Pine, Jan Philipp Bewersdorf, Rory Michael Shallis, Maximilian Stahl, Amer M Zeidan
Getting personal with myelodysplastic syndromes: is now the right time? Expert review of hematology 12 (4) (2019)
Rory Michael Shallis, Jan Philipp Bewersdorf, Prajwal C Boddu, Amer M Zeidan
Hedgehog pathway inhibition as a therapeutic target in acute myeloid leukemia. Expert review of anticancer therapy 19 (8) (2019)
Rory Michael Shallis, Nikolai Podoltsev
What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly? Expert opinion on pharmacotherapy 20 (10) (2019)
Rory Michael Shallis, Rami Ahmad, Amer M Zeidan
Aplastic anemia: Etiology, molecular pathogenesis, and emerging concepts. European journal of haematology 101 (6) (2018)
Rory Michael Shallis, Rami Ahmad, Amer M Zeidan
The genetic and molecular pathogenesis of myelodysplastic syndromes. European journal of haematology 101 (3) (2018)
Rory M Shallis, Rory Michael Shallis
More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC hematology 18 (2018)
Rory Michael Shallis, Nora Chokr, Maximilian Stahl, Alexander B Pine, Amer M Zeidan
Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert review of hematology 11 (9) (2018)